CN109996558A - 心力衰竭和心脏缺血再灌注损伤的治疗 - Google Patents

心力衰竭和心脏缺血再灌注损伤的治疗 Download PDF

Info

Publication number
CN109996558A
CN109996558A CN201780073002.5A CN201780073002A CN109996558A CN 109996558 A CN109996558 A CN 109996558A CN 201780073002 A CN201780073002 A CN 201780073002A CN 109996558 A CN109996558 A CN 109996558A
Authority
CN
China
Prior art keywords
shock wave
inhibitor
dpp
heart
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780073002.5A
Other languages
English (en)
Chinese (zh)
Inventor
萨洛蒙·纳若登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN109996558A publication Critical patent/CN109996558A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/225—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780073002.5A 2016-11-24 2017-11-17 心力衰竭和心脏缺血再灌注损伤的治疗 Pending CN109996558A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619861.6A GB201619861D0 (en) 2016-11-24 2016-11-24 Treatments for heart failure and cardiac ischaemic reperfusion injury
GB1619861.6 2016-11-24
PCT/GB2017/053473 WO2018096319A1 (en) 2016-11-24 2017-11-17 Treatments for heart failure and cardiac ischaemic reperfusion injury

Publications (1)

Publication Number Publication Date
CN109996558A true CN109996558A (zh) 2019-07-09

Family

ID=58073526

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780073002.5A Pending CN109996558A (zh) 2016-11-24 2017-11-17 心力衰竭和心脏缺血再灌注损伤的治疗

Country Status (16)

Country Link
US (1) US20190374623A1 (https=)
EP (1) EP3544624B1 (https=)
JP (1) JP7231543B2 (https=)
KR (1) KR102678011B1 (https=)
CN (1) CN109996558A (https=)
AU (1) AU2017365926B2 (https=)
CA (1) CA3044624A1 (https=)
ES (1) ES3017482T3 (https=)
GB (1) GB201619861D0 (https=)
HR (1) HRP20250664T1 (https=)
HU (1) HUE071244T2 (https=)
MY (1) MY200960A (https=)
PL (1) PL3544624T3 (https=)
RS (1) RS66778B9 (https=)
RU (1) RU2767445C2 (https=)
WO (1) WO2018096319A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023281447A1 (en) * 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event
US20240122794A1 (en) * 2022-10-12 2024-04-18 Softwave Tissue Regeneration Technologies, Inc. Acoustic shock wave or pressure pulse treatment and methods of use for anti-aging
CN115998768B (zh) * 2023-02-07 2024-01-30 西南医科大学 M2型巨噬细胞外泌体在制备治疗心肌缺血再灌注损伤药物中的应用
CN117257785A (zh) * 2023-11-09 2023-12-22 新疆医科大学 没食子酸及其衍生物在制备预防和/或治疗心肌损伤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090286730A1 (en) * 2006-04-19 2009-11-19 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
US20090297470A1 (en) * 2006-04-19 2009-12-03 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
CN102448456A (zh) * 2009-03-27 2012-05-09 百时美施贵宝公司 用dpp-iv抑制剂预防重度有害心血管事件的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3110449B1 (en) * 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090286730A1 (en) * 2006-04-19 2009-11-19 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
US20090297470A1 (en) * 2006-04-19 2009-12-03 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
CN102448456A (zh) * 2009-03-27 2012-05-09 百时美施贵宝公司 用dpp-iv抑制剂预防重度有害心血管事件的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MADOKA IHARA等: "An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury", 《AMERICAN JOURNAL OF PHYSIOLOGY: HEART AND CIRCULATORY PHYSIOLOGY》 *
王喜梅等: "二肽基肽酶4抑制剂心血管保护作用的研究进展", 《心血管病学进展》 *

Also Published As

Publication number Publication date
GB201619861D0 (en) 2017-01-11
RS66778B1 (sr) 2025-06-30
WO2018096319A1 (en) 2018-05-31
RU2767445C2 (ru) 2022-03-17
RU2019119110A3 (https=) 2021-08-30
JP2020510616A (ja) 2020-04-09
PL3544624T4 (pl) 2025-11-03
JP7231543B2 (ja) 2023-03-01
MY200960A (en) 2024-01-26
HUE071244T2 (hu) 2025-07-28
EP3544624C0 (en) 2025-02-12
HRP20250664T1 (hr) 2025-10-24
RU2019119110A (ru) 2020-12-24
KR20190100199A (ko) 2019-08-28
PL3544624T3 (pl) 2025-11-03
US20190374623A1 (en) 2019-12-12
KR102678011B1 (ko) 2024-06-25
EP3544624B1 (en) 2025-02-12
AU2017365926A1 (en) 2019-07-04
CA3044624A1 (en) 2018-05-31
ES3017482T3 (en) 2025-05-13
EP3544624A1 (en) 2019-10-02
AU2017365926B2 (en) 2025-06-05
RS66778B9 (sr) 2025-08-29

Similar Documents

Publication Publication Date Title
US8455435B2 (en) Remedies for ischemia
KR102678011B1 (ko) 심부전 및 심장 허혈성 재관류 손상 치료
KR20170137919A (ko) 조직 복구 및 재생 방법
JP2021155433A (ja) １型肝腎症候群患者の治療方法
Brenner et al. Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells
CN101939014A (zh) 亚硝酸盐在慢性缺血中的应用
JP2014533697A (ja) デフェリプロンを用いた処置方法
Zeng et al. Impairment of Cardiac Function and Remodeling Induced by Myocardial Infarction in Rats are Attenuated by the Nonpeptide Angiotensin‐(1–7) Analog AVE 0991
WO2017152039A1 (en) Protection and delivery of multiple therapeutic proteins
Rajani et al. Post-infarct morphine treatment mitigates left ventricular remodeling and dysfunction in a rat model of ischemia-reperfusion
Zhang et al. Efficacy and safety of intracoronary autologous bone marrow‐derived cell transplantation in patients with acute myocardial infarction: insights from randomized controlled trials with 12 or more months follow‐up
JP2008540456A (ja) 血管疾患の治療
JP2019507174A (ja) 心血管疾患におけるリラグルチド
Miura et al. The histological features of a myocardial biopsy specimen in a patient in the acute phase of reversible catecholamine-induced cardiomyopathy due to pheochromocytoma
US8889122B2 (en) Cellular cardiomyoplasty as supportive therapy in patients with heart disease
CN117159549B (zh) 一种酯类化合物的应用
CN108201538A (zh) 褪黑素在促进心肌干细胞移植治疗心肌梗死中的应用
CN114917346B (zh) 用于缺血性心脏病治疗的药物及药物组合物
US20090012499A1 (en) Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (igf-1)
Hoette et al. Dual receptor blockade by bosentan: clinical experience in treatment of pulmonary hypertension
辻野泰 Edoxaban suppresses the Progression of Atrial Fibrosis and Atrial Fibrillation in a Canine Congestive Heart Failure Model.
Imamura et al. Plasma C-reactive protein level is increased in patients with severe heart failure
Ito et al. Efficacy of combined therapy with DOA, DOB, and HANP in severe congestive heart failure due to cardiac sarcoidosis
Lien et al. P1-23 G-CSF AUGMENTS IRON OVERLOAD CARDIAC DYSFUNCTION AND PROMOTES INFLAMMATORY DEPENDENT CARDIAC THROMBOSIS IN MICE
Nikolaeva et al. Results of the Cardiological Study Invest: A New Word in the Therapy of Patients with Hypertension

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination